Email Updates

Place quotation marks around exact phrases (e.g. "new york"). Note: Trial names have a space before the number (e.g. HVTN 100).

You are here

Home

Trial Search

Trial Name Prevention Option Phase Start Date Sponsors Countries Population Candidate(s) Status
AAAS 1239 HIV Vaccine I April 2019 Bill and Melinda Gates Foundation, International AIDS Vaccine Initiative, The Emmes Company, LLC United States of America Men, Women 10E8.4/iMab Ongoing
HVTN 139 HIV Vaccine I November 2021 HIV Vaccine Trials Network; NIAID South Africa Men, Women AdC6-HIVgp140, AdC7-HIVgp140, CH505TF, GLA-SE, gp120 Ongoing
ANRS VRI06 HIV Vaccine I March 2021 ANRS, Emerging Infectious Diseases France, Switzerland Men, Women CD40.HIVRI.Env, DNA-HIV-PT123, Poly-ICLC Ongoing
RV 460 HIV Vaccine I March 2021 NIAID, US Army Medical Research Directorate-Africa, US Military HIV Research Program, WRAIR Kenya Men, Women Env gp145 C.6980 protein, Env-C Plasmid DNA, Rehydragel, ALF43, dmLT Ongoing
RV 546 HIV Vaccine I January 2022 U.S. Army Medical Research and Development Command Men IHV01 A244, AHFG ALFQ adjuvant Ongoing
HVTN 135 HIV Vaccine I November 2020 NIAID, HVTN South Africa Adolescent/Children CH505TF, GLA-SE, gp120 Ongoing
HIV-CORE 006 HIV Vaccine I August 2021 University of Oxford, EDCTP, IAVI, University of Nairobi, KEMRI-Wellcome Kenya, Rwanda, Uganda, Zambia Men, Women ChAdOx1.tHIVconsv1, MVA.tHIVcnsv4, MVA.tHIVconsv3 Ongoing
IAVI C101 HIV Vaccine I August 2020 IAVI, GSK United States of America, Netherlands Men, Women BG505 SOSIP GT1.1 gp140 Ongoing
ACTHIVE-001 HIV Vaccine I November 2019 Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) Netherlands Men ConM SOSIP.v7, gp140 Ongoing
19-I-0069 HIV Vaccine I April 2019 NIAID United States of America Men, Women Ad4-Env150KN, VRC-HIVRGP096-00-VP, Ad4-Env145NFL Ongoing
WHV 138 HIV Vaccine I July 2021 Worcester HIV Vaccine, IDRI, Target Health, LLC, NIAID United States of America Men DNA , Protein Ongoing
VIR-111-2001 HIV Vaccine I December 2020 Gates Foundation United States of America Men, Women Ongoing
HVTN 140/ HPTN 101 HIV Vaccine Open Label November 2021 NIAID (DAIDS-ES: 38723) United States of America, Kenya, South Africa, Zimbabwe Men PGDM1400LS, PGT121.414.LS, VRC07-523LS Ongoing
HVTN 136/ HPTN 092 HIV Vaccine I November 2020 NIAID (DAID-ES: 38634) United States of America Men, Women PGT121.414.LS, VRC07-523LS Ongoing
IAVI G003 HIV Vaccine I May 2022 South Africa, Rwanda Men, Women mRNA-1644 (eOD-GT8 60mer) Ongoing
HVTN 302 HIV Vaccine Open Label February 2022 NIAID (DAIDS-ES ID: 38791) United States of America Men, Women BG505 MD39.3 mRNA, BG505 MD39.3 gp151 mRNA, BG505 MD39.3 gp151 CD4KO mRNA Ongoing
HVTN 300 HIV Vaccine I May 2021 NIAID United States of America Men CH505TF Ongoing
IAVI G002 HIV Vaccine I November 2021 International AIDS Vaccine Initiative; ModernaTX, Inc.; The University of Texas at San Antonio; George Washington University; Fred Hutchinson Cancer Research Center; Emory University United States of America Men, Women mRNA-1644 (eOD-GT8 60mer) Ongoing
HVTN 706/ HPX3002/ Mosaico HIV Vaccine III October 2019 Janssen Vaccines & Prevention B.V. United States of America, Argentina, Italy, Mexico, Peru, Poland, Spain Men Ad26.Mos4.HIV, gp140 Ongoing
PrEPVacc / PV1 HIV Vaccine, PrEP IIb January 2020 Sponsor: Imperial College London. Coordinating partners: P Kaleebu, E Ruzagira (MRC/UVRI & LSHTM, Uganda); J Weber/J Fox/C Kingsley (Imperial College, UK); S McCormack (UCL, UK); K Chinyenze (IAVI-Kenya); G Pantaleo/S Ding (CHUV/EVF, Switzerland) Uganda, South Africa, United Republic of Tanzania, Mozambique Men, Women DNA , MVA, Protein Ongoing

Pages

CSVDoc